PARATEK PHARMACEUTICALS, INC.

Paratek to Present Groundbreaking Clinical Data on NUZYRA for NTM and CABP at ATS 2025

6 days ago

• Paratek Pharmaceuticals will present results from two significant clinical studies of NUZYRA (omadacycline) at the ATS 2025 International Conference, including the first-ever placebo-controlled trial in Mycobacterium abscessus complex pulmonary disease. • The Phase 2b study in nontuberculous mycobacterial pulmonary disease (NTM PD) addresses a significant unmet need, while the Phase 3 OPTIC-2 study confirms NUZYRA's efficacy and safety profile in community-acquired bacterial pneumonia. • NUZYRA, a next-generation tetracycline designed to overcome resistance, has established the largest clinical trial dataset in pneumonia across all antibiotics approved by the FDA in the last decade.

Zai Lab's Augtyro Included in China's National Reimbursement Drug List for ROS1+ NSCLC

6 months ago

• Zai Lab's Augtyro (repotrectinib) has been added to China's National Reimbursement Drug List (NRDL) for treating adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). • The NRDL update also includes the renewal of Nuzyra (omadacycline) for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). • Qinlock (ripretinib) is also renewed for advanced gastrointestinal stromal tumor (GIST) patients who have received prior treatment with three or more kinase inhibitors. • The inclusion of these drugs in the NRDL aims to improve patient access to innovative treatments at more affordable costs throughout China.